From Our Partners
Wednesday, July 6, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home CBRNE

Identifying and Optimizing Chemical Threat Countermeasures

by Global Biodefense Staff
March 14, 2016
NIH CounterACT Chemical Countermeasure Program

The National Institutes of Health (NIH) Countermeasures Against Chemical Threats (CounterACT) program has released two new funding opportunities to support identification and optimization of therapeutics to treat exposures to chemical warfare agents and toxic industrial chemicals.

The civilian chemical threat spectrum includes chemical warfare agents (e.g., sarin), toxic industrial chemicals (e.g., cyanide), pesticides (e.g., parathion), and other chemicals.

NIH CounterACT cooperative agreement projects will support studies to generate the tools, efficacy in an appropriate animal model, and safety and pharmacology data necessary to transition the proposed therapeutics to advanced drug development, regulatory approval, and licensure.

Identification of Therapeutic Lead Compounds

PAR-16-129

Supports research on the identification of small molecule or biologic lead compounds that are excellent candidates for therapeutic development. Includes confirmation of molecular targets for therapeutic development, demonstration of in vitro activity of candidate therapeutics, preliminary in vivo proof-of-concept efficacy data, preliminary adsorption, distribution, metabolism, excretion, and toxicity (ADME/Tox) evaluations and pharmacokinetics/pharmacodynamics (PK/PD) data.

Optimization of Therapeutic Lead Compounds

PAR-16-128

The scope of research supported includes development of appropriate human-relevant animal models and generation of in vivo efficacy data consistent with the intended use of the product in humans.  It also includes bioanalytical assay development and validation, laboratory-scale and scale-up manufacturing of the product, and non-GLP toxicity and pharmacology studies. A previously identified lead compound is required to be eligible for this funding opportunity.

Funding for this effort will only support the development of lead compounds that can be used to reduce mortality or serious morbidity during a chemical emergency. The primary focus is on post-exposure efficacy; compounds that are only effective if administered prior to the chemical insult (prophylaxis efficacy) will be of lowest priority.

Applicants are encouraged to collaborate with laboratories that are already certified and legally authorized to work with restricted chemical agents, such as the U.S. Army Medical Research Institute of Chemical Defense (USAMRICD) and certain contract research organizations, when applicable.

From Our Partners
Tags: Animal ModelsNIHRequest for Proposals

Related Posts

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control
Medical Countermeasures

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Biodefense Industry News
Industry News

Tonix Pharmaceuticals Opens Advanced Development Center for Vaccine Programs

June 20, 2022
Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine
Medical Countermeasures

Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine

May 30, 2022
Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors
Industry News

Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors

May 26, 2022
Load More

Latest News

Biodefense Headlines – 5 July 2022

Biodefense Headlines – 5 July 2022

July 5, 2022
Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

June 22, 2022
Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

June 22, 2022
UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC